Applied Therapeutics posted a $19M net loss in Q3 2025 on $1M in licensing revenue, with reduced R&D and G&A costs helping to shrink losses compared to the prior year.

Applied Therapeutics reported a net loss of $21.8 million for the first quarter of 2025, with total revenue at $0. Cash and cash equivalents decreased to $50.8 million. The company is focused on advancing govorestat programs and preparing for regulatory interactions.

Applied Therapeutics reported financial results for Q3 2024, highlighting progress in regulatory submissions for govorestat in Classic Galactosemia and SORD Deficiency. The company is preparing for commercialization, with NDA review ongoing for Classic Galactosemia and NDA submission expected for SORD Deficiency in early Q1 2025. Cash and cash equivalents totaled $98.9 million. Net loss for the quarter was $68.6 million.

Applied Therapeutics reported a net income of $2.9 million for the second quarter of 2024, a significant improvement compared to a net loss of $29.6 million for the same period in 2023. The company is progressing with regulatory submissions for govorestat in Classic Galactosemia and SORD Deficiency.

Applied Therapeutics reported its first quarter 2024 financial results, highlighting preparations for the potential approval and commercial launch of govorestat for Classic Galactosemia in the US and EU. The company is also in discussions regarding a potential NDA submission for SORD Deficiency with the FDA.

Applied Therapeutics reported fourth quarter and full year financial results, highlighting clinical and regulatory progress with govorestat for Galactosemia, including NDA acceptance and MAA validation. Positive data from the INSPIRE study in SORD Deficiency was announced, and the company plans to request a pre-NDA meeting with the FDA. A $100 million private placement strengthened the balance sheet, extending the cash runway into 2026.

Applied Therapeutics reported its third quarter 2023 financial results, highlighting progress in its late-stage pipeline and upcoming regulatory and clinical milestones. Key activities include the planned regulatory filings for govorestat for Classic Galactosemia and upcoming Phase 3 trial readouts for ARISE-HF and INSPIRE trials.

Applied Therapeutics reported on their progress in advancing programs across Galactosemia, SORD Deficiency and Diabetic Cardiomyopathy in the second quarter of 2023.

Applied Therapeutics reported its Q1 2023 financial results, highlighting the long-term clinical benefit of Govorestat in the ACTION-Galactosemia Kids Trial and a strengthened balance sheet with a $30 million private placement of equity. Phase 3 INSPIRE trial of Govorestat in Sorbitol Dehydrogenase (SORD) Deficiency and ARISE-HF Trial of AT-001 in Diabetic Cardiomyopathy are on track for data in 2023.

Applied Therapeutics reported financial results for the fourth quarter and full year ended December 31, 2022, highlighting clinical progress in Phase 3 programs and a deal with Advanz Pharma.

Applied Therapeutics reported on their progress across all three late-stage programs, focusing on completing Phase 3 trials in Galactosemia, SORD Deficiency, and Diabetic Cardiomyopathy. They anticipate sharing data in 2023, which could lead to new treatment options for patients with limited or no available therapies.

Applied Therapeutics reported financial results for the second quarter ended June 30, 2022, and continued progress across its three registrational Phase 3 trials in Galactosemia, SORD Deficiency and Diabetic Cardiomyopathy.

Applied Therapeutics reported financial results for the first quarter ended March 31, 2022, with continued progress in three Phase 3 trials and multiple clinical milestones expected in 2022.

Applied Therapeutics reported financial results for the fourth quarter and full year ended December 31, 2021, highlighting progress in three Phase 3 trials and expectations for multiple clinical and regulatory milestones in 2022.

Applied Therapeutics announced positive data from studies in Galactosemia and SORD Deficiency, and is preparing for a commercial launch in Galactosemia in 2022 and a registrational study in SORD later in 2021.

Applied Therapeutics reported its Q2 2021 financial results, highlighting the advancement of their pediatric Galactosemia program and preparations for NDA submission in Q3 2021. The company ended the quarter with a strong balance sheet, holding $125.6 million in cash and cash equivalents.

Applied Therapeutics reported its Q1 2021 financial results, highlighting the progression of late-stage programs towards commercialization in Galactosemia and Diabetic Cardiomyopathy, and advancement of rare disease programs in SORD and PMM2-CDG. The company ended the quarter with $148.1 million in cash and cash equivalents and short-term investments.

Applied Therapeutics reported financial results for the fourth quarter and full year ended December 31, 2020, with a focus on advancing late-stage assets toward commercialization and initiating clinical development of new rare disease programs.

Applied Therapeutics reported on their Diabetic Cardiomyopathy program, with continued enrollment in the ARISE-HF global Phase 3 registrational study. They are preparing for new rare disease clinical programs in SORD Deficiency and PMM2-CDG, planned to start in 2021, and are collaborating with the FDA to restart the ACTION-Galactosemia Kids pediatric study.

Applied Therapeutics reported its financial results for the second quarter ended June 30, 2020, while continuing to advance its late-stage programs towards regulatory submission and commercial launch.

Applied Therapeutics reported financial results for the first quarter ended March 31, 2020, highlighting a period of tremendous growth and advancement across its clinical programs. The company is building out its commercial infrastructure and remains well capitalized.

Applied Therapeutics reported its Q4 and full-year 2019 financial results, highlighting a transformative year with progress in clinical development programs for Diabetic Cardiomyopathy and Galactosemia.